nach oben

Erschienen in:

01.09.2008 | Case Report

Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline

verfasst von: Giovanna Aparecida Balarini Lima, Evelyn de Oliveira Machado, Cintia Marques dos Santos Silva, Paulo Niemeyer Filho, Mônica Roberto Gadelha

Erschienen in: Pituitary | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Pituitary apoplexy is a rare and life-threatening clinical condition caused by hemorrhage and/or infarction of the pituitary gland or adenoma. Although pituitary apoplexy is usually spontaneous, it has been associated with numerous precipitating factors, such as bromocriptine use. However, reports of pituitary apoplexy during cabergoline therapy are scarce. We report three patients with cystic macroprolactinomas who developed pituitary apoplexy during cabergoline treatment.

Brougham M, Heusner AP, Adams RD (1950) Acute degenerative changes in adenomas of the pituitary body – with special reference to pituitary apoplexy. J Neurosurg 7:421–439PubMed

Rovit RL, Fein JM (1972) Pituitary apoplexy: a review and repraisal. J Neurosurg 37:280–288PubMed

Mohr G, Hardy J (1982) Hemorrhage, necrosis, and apoplexy in pituitary adenomas. Surg Neurol 18:181–189PubMedCrossRef

Rolih CA, Ober KP (1993) Pituitary apoplexy. Endocrinol Metab Clin N Am 22:291–302

Bonicki W, Kasperlik-Zaluska A, Koszewski W, Zgliczynski W, Wislawski J (1993) Pituitary apoplexy: endocrine, surgical and oncological emergency Incidence, clinical course and treatment with reference to 799 cases of pituitary adenomas. Acta Neurochir (Wien) 120:118–122CrossRef

Pinheiro MM, Cukiert A, Salgado LR, Nery M, Goldman J, Pimentel F, Liberman B (1999) Asymptomatic apoplexy in pituitary tumors. Arq Neuro-Psiquiat 57:74–77

Tamasawa N, Kurahashi K, Baba T, Hishita R, Murabayashi S, Kashiwamura H, Takebe K (1988) Spontaneous remission of acromegaly after pituitary apoplexy following head trauma. J Endocrinol Invest 11:429–432PubMed

Reid RL, Quigley ME, Yen SS (1985) Pituitary apoplexy. A review. Arch Neurol 42:712–719PubMed

Randeva HS, Schoebel J, Byrne J, Esiri M, Adams CB, Wass JA (1999) Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol (Oxf) 51:181–188CrossRef

10.

Eisberg LA (1977) Pituitary apoplexy. Association of degenerative change in pituitary adenoma with radiotherapy and detection by cerebral computed tomography. Am J Med 63:109–115CrossRef

11.

Otsuka F, Kageyama J, Ogura T, Makino H (1998) Pituitary apoplexy induced by a combined anterior pituitary test: case report and review of the literature. Endocr J 45:393–398PubMedCrossRef

12.

Levy A (2003) Hazards of dynamic testing of pituitary function. Clin Endocrinol (Oxf) 58:543–544CrossRef

13.

Alzetani A, Fisher C, Costa R, Ohri SK (2002) Ptose postcardiac surgery: a case of pituitary apoplexy. Ann Thorac Surg 73:300–301PubMedCrossRef

14.

Maiza JC, Bennet A, Thom-Kany M, Lagarrigue J, Caron P (2004) Pituitary apoplexy and idiopathic thrombocytopenic purpura: a new case and review of the literature. Pituitary 7:189–192PubMedCrossRef

15.

Nagarajan DV, Bird D, Papouchado M (2003) Pituitary apoplexy following anticoagulation for acute coronary syndrome. Heart 89:10PubMedCrossRef

16.

Yamaji T, Ishibashi M, Kosaka K, Fukushima T, Hori T, Manaka S, Sano K (1981) Pituitary apoplexy in acromegaly during bromocriptine therapy. Acta Endocrinol (Copenh) 98:171–177

17.

Shirataki K, Chihara K, Shibata Y, Tamaki N, Matsumono S, Fujita T (1988) Pituitary apoplexy manifested during a bromocriptine test in a patient with a growth hormone- and prolactin-producing pituitary adenoma. Neurosurgery 23:395–398PubMedCrossRef

18.

Alhajje A, Lambert M, Crabbe J (1985) Pituitary apoplexy in an acromegalic patient during bromocriptine therapy. Case report. J Neurosurg 63:288–292PubMed

19.

Pinto G, Zerah M, Trivin C, Brauner R (1998) Pituitary apoplexy in an adolescent with prolactin-secreting adenoma. Horm Res 50:38–41PubMedCrossRef

20.

Yang BP, Yang CW, Mindea SA, Tomita T (2005) Pituitary apoplexy. Pediatr Radiol 35:830–831PubMedCrossRef

21.

Yahagi N, Nishikawa A, Matsui S, Komoda Y, Sai Y, Amakata Y (1992) Pituitary apoplexy following cholecystectomy. Anaesthesia 47:234–236PubMedCrossRef

22.

Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO (1985) Bromocriptine as primary medical therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60:698–705PubMed

23.

Molitch ME (1999) Medical treatment of prolactinomas. Endocrinol Metab Clin N Am 28:143–169CrossRef

24.

Bevan JS, Webster J, Christopher WB (1992) Dopamin agonist and pituitary tumor shrinkage. Endocr Rev 13:220–240PubMedCrossRef

25.

Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet CP, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A (1989) Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69:500–509PubMed

26.

Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) for the Cabergoline Comparative Study Group. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 331:904–909PubMedCrossRef

27.

Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G (1997) Prolactinomas resistant to dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 82:876–883PubMedCrossRef

28.

Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518–2522PubMedCrossRef

29.

Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, Schoenfelder JR, Klibanski A (1996) Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 81:2338–2343PubMedCrossRef

30.

Knoepfelmacher M, Gomes MC, Melo ME, Mendonça BB (2004) Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma. Pituitary 7:83–87PubMedCrossRef

31.

Ebersold MJ, Laws ERJr, Scheithauer BW, Randall RV (1983) Pituitary apoplexy treated by transsphenoidal surgery. A clinicopathological and immunocytochemical study. J Neurosurg 58:315–320PubMed

32.

Arafah BM, Harrington JF, Madhoun ZT, Selman WR (1990) Improvement of pituitary function after surgical decompression for pituitary tumor apoplexy. J Clin Endocrinol Metab 71:323–328PubMed

33.

Bills DC, Meyer FB, Laws ER Jr, Davis DH, Ebersold MJ, Scheithauer BW, Ilstrup DM, Abboud CF (1993) A retrospective analysis of pituitary apoplexy. Neurosurgery 33:602–608PubMedCrossRef

34.

Maccagnan P, Macedo CL, Kayath MJ, Nogueira RG, Abucham J (1995) Conservative management of pituitary apoplexy: a prospective study. J Clin Endocrinol Metab 80:2190–2197PubMedCrossRef

35.

Ayuk J, McGregor EJ, Mitchell RD, Gittoes NJL (2004) Acute management of pituitary apoplexy – surgery or conservative management? Clin Endocrinol (Oxf) 61:747–752CrossRef

36.

Wakai S, Fukushima T, Teramoto A, Sano K (1981) Pituitary apoplexy: its incidence and clinical significance. J Neurosurg 55:187–193PubMed

37.

Cardoso ER, Peterson EW (1984) Pituitary apoplexy: a review. Neurosurgery 14:363–373PubMedCrossRef

38.

Enjalbert A, Bockaert J (1983) Pharmacological characterization of D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary. Mol Pharmacol 23:576–584PubMed

39.

De Camille P, Macconi P, Spada A (1979) Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas. Nature 278:252–254CrossRef

40.

Brocas H, Van Coevorden A, Seo H, Refetoff S, Vassart G (1981) Dopaminergic control of prolactin mRNA accumulation in the pituitary of the male rat. Mol Cell Endocrinol 22:25–30PubMedCrossRef

41.

Maurer RA (1981) Transcriptional regulation of the prolactin gene by ergocryptine and cyclic AMP. Nature 294:94–97PubMedCrossRef

42.

Shull JD, Gorski J (1990) Regulation of prolactin gene transcription in vivo: interactions between estrogen, pimozide, and alpha-ergocryptine. Mol Pharmacol 37:215–221PubMed

43.

Landolt AM, Minder H, Osterwalder V, Landolt TA (1983) Bromocriptine reduces the size of cells in prolactin-secreting pituitary adenomas. Experientia 39:625–626PubMedCrossRef

44.

Gen M, Uozumi T, Ohta M, Ito A, Kajiwara H, Mori S (1984) Necrotic changes in prolactinomas after long-term administration of bromocriptine. J Clin Endocrinol Metab 59:463–470PubMedCrossRef

45.

Mori H, Mori S, Saitoh Y, Arita N, Aono T, Uozomi T, Mogami H, Matsumoto K (1985) Effects of bromocriptine on prolactin-secreting pituitary adenomas Mechanism of reduction in tumor cell size evaluated by light and electron microscopic, immunohistochemical, and morphometric analysis. Cancer 56:230–238PubMedCrossRef

46.

Rengachary SS, Tomita T, Jefferies BF, Watanabe I (1982) Structural changes in human pituitary tumor after bromocriptine therapy. Neurosurgery 10:242–251PubMedCrossRef

47.

Tindall GT, Kovacs K, Horvath E, Thorner MO (1982) Human prolactin-producing adenomas and bromocriptine. A histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 55:1178–1183PubMed

48.

Barrow DL, Tindall GT, Kovacs K, Thorner MO, Horvarth E, Hoffman JC Jr (1984) Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors. J Neurosurg 60:1–7PubMedCrossRef

49.

Kovacs K, Stefaneanu L, Horvath E, Lloyd RV, Lancranjan I, Buchfelder M, Fahlbusch R (1991) Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization. Virchows Arch A Pathol Anat Histopathol 418:439–446PubMedCrossRef

50.

Landolt AM, Osterwalder V (1984) Perivascular necrosis in prolactinomas: is it increased by bromocriptine?. J Clin Endocrinol Metab 58:1179–1183PubMed

51.

Lloyd HM, Meares JD, Jacobi J (1975) Effects of oestrogen and bromocriptine on in vivo secretion and mitosis in prolactin cells. Nature 255:497–498PubMedCrossRef

52.

Kontogeorgos G, Horvath E, Kovacs K, Coire C, Lloyd RV, Scheithauer BW, Smyth HS (2006) Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists. Acta Neuropathol 111:46–52PubMedCrossRef

53.

Yousem DM, Arrington JA, James Zinhreich S, Kumar AJ, Nick Bryan R (1989) Pituitary adenomas: possible role of bromocriptine in intratumoral hemorrhage. Radiology 170:239–243PubMed

54.

Lundin P, Nyman R, Burman P, Lundberg PO, Muhr C (1992) MRI of pituitary macroadenomas with reference to hormonal activity. Neuroradiol 34:43–51CrossRef

55.

Delgrange E, Gustin T (2005) Cystic macroprolactinoma: primary medical treatment? Intern Med J 35:687–688PubMedCrossRef

Titel: Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline
verfasst von: Giovanna Aparecida Balarini Lima
Evelyn de Oliveira Machado
Cintia Marques dos Santos Silva
Paulo Niemeyer Filho
Mônica Roberto Gadelha
Publikationsdatum: 01.09.2008
Verlag: Springer US
Erschienen in: Pituitary / Ausgabe 3/2008
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-007-0046-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2008

The GnRH test in the assessment of patients with pituitary and parapituitary lesions: results of a 5-year retrospective study

Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study

Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation?

Quality of life in women with microprolactinoma treated with dopamine agonists

A case of macroprolactinoma encasing an internal carotid artery aneurysm, presenting as pituitary apoplexy